Charles River Laboratories International, Inc.
CRL
$175.92
$6.653.93%
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00B | 1.01B | 1.03B | 1.01B | 1.01B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00B | 1.01B | 1.03B | 1.01B | 1.01B |
| Cost of Revenue | 688.77M | 642.00M | 658.39M | 658.79M | 659.22M |
| Gross Profit | 313.78M | 367.77M | 367.73M | 352.77M | 354.25M |
| SG&A Expenses | 194.43M | 187.01M | 165.16M | 177.02M | 194.33M |
| Depreciation & Amortization | 41.22M | 32.40M | 32.27M | 32.58M | 34.02M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 924.43M | 861.41M | 855.81M | 868.38M | 887.57M |
| Operating Income | 78.12M | 148.35M | 170.31M | 143.18M | 125.91M |
| Income Before Tax | -216.79M | 91.24M | 119.65M | 99.01M | 208.71M |
| Income Tax Expenses | -3.04M | 20.95M | 25.39M | 24.53M | 19.75M |
| Earnings from Continuing Operations | -213.75M | 70.30M | 94.26M | 74.48M | 188.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -748.00K | -638.00K | -180.00K | -1.52M | -1.87M |
| Net Income | -214.50M | 69.66M | 94.08M | 72.96M | 187.08M |
| EBIT | 78.12M | 148.35M | 170.31M | 143.18M | 125.91M |
| EBITDA | 170.83M | 236.55M | 256.39M | 228.53M | 206.42M |
| EPS Basic | -4.22 | 1.34 | 1.75 | 1.31 | 3.65 |
| Normalized Basic EPS | 0.41 | 1.47 | 1.67 | 1.38 | 1.27 |
| EPS Diluted | -4.22 | 1.33 | 1.74 | 1.30 | 3.62 |
| Normalized Diluted EPS | 0.41 | 1.47 | 1.66 | 1.37 | 1.26 |
| Average Basic Shares Outstanding | 51.14M | 51.39M | 51.55M | 51.44M | 51.31M |
| Average Diluted Shares Outstanding | 51.14M | 51.58M | 51.85M | 51.77M | 51.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
